Gan & Lee Pharmaceuticals Co Ltd (603087)
Shanghai Stock Exchange · China · prices in CNY · close of 23 Oct 2026
Key indicators
| Last close | CNY 72.00 |
|---|---|
| 52-week range | 51.51 – 79.99 |
| Return, 1 month / 3 months | −3.4% / +8.0% |
| Return, 1 year / 3 years | +5.4% / +61.4% |
| Trend | Uptrend |
| RSI (14) | 53 |
| Volatility (1 year) | 40.8% |
| Worst drawdown (1 year) | -29.6% |
| Average daily value traded | 739.22M CNY |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Gan & Lee Pharmaceuticals is a Chinese pharmaceutical company based in Beijing that focuses on diabetes treatments. It develops and manufactures recombinant human insulin and insulin analogue products, including long-acting and rapid-acting insulins, along with other biopharmaceutical medicines. Its customers are mainly hospitals, clinics and patients managing diabetes in China and in overseas markets where its products are registered. The company also carries out research on further protein and peptide-based therapies.
On this site Gan & Lee Pharmaceuticals Co Ltd appears as a stock on the Shanghai Stock Exchange (China), code 603087, with prices in Chinese yuan (CNY). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Gan & Lee Pharmaceuticals Co Ltd (603087) trades on the Shanghai Stock Exchange in China. It last closed at CNY 72.00 on 23 October 2026.
Its price-based Market X-Ray is 84 out of 100 (a strong price profile), ranking 35 of 2,278 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 5.4% and over the last three months it rose 8.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Shanghai Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 95 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 10.8% | ||
| From 52-week high | -7.1% | ||
| Momentum | 81 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 8.0% | ||
| 6-month return | 21.0% | ||
| 12-month return, skipping the last month | 9.1% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 40.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.6% | ||
| Liquidity | 89 · Strong | Trades actively. | |
| Average daily value traded | 739.22M CNY | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +3.1% |
|---|---|
| 1 month | −3.4% |
| 3 months | +8.0% |
| 6 months | +21.0% |
| 1 year | +5.4% |
| 3 years | +61.4% |
| 5 years | +2.3% |
Signals
| 50-day / 200-day average | 70.99 / 64.97 |
|---|---|
| Golden / death cross (60 days) | Golden, 43 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.23 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 20 Jun 2022 | CNY 0.3000 |
| 21 May 2021 | CNY 0.4000 |
| 20 Aug 2020 | CNY 0.7000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shanghai Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.